

APBMT Annual Report 2022

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT



Copyright APBMT Annual Report 2022

Worldwide Confidentiality Note: Dissemination, distribution or copying of this document or the information herein by anyone other than the approved recipient is prohibited. If you are not the intended recipient, please inform APBMT Secretariat (office@apbmt.org).

Prior approval must be sought from APBMT before releasing any data from this document publicly, and APBMT must be acknowledged as the data source. The suggested citation is : "APBMT Annual Report 2022".

This document contains information on hematopoietic stem cell transplants and cellular therapies provided voluntarily by participating countries/regions in the Asia-Pacific region. The data and its analysis are the property of APBMT. This APBMT resource is intended for use by its members and approved participating clinical and research organizations.

While all care has been taken in the compilation of this document, no responsibility can be taken for misuse of the data or for data errors that have been unintentionally included.



**Asia-Pacific Blood and Marrow
Transplantation Group
(APBMT)
Annual Report
2022**

Secretariat Office / Data Center of APBMT

**E-mail: office@apbmt.org
Website: <https://www.apbmt.org>**

Contents

Introduction

- General Overview 2022
- Bylaws
- Organizational Tree
- Principal Member List

Annual Congresses

- Guidelines for the hosting of the APBMT annual congress
- Previous and Future Congresses
- The Number of Attendees for Each Annual Congress from 2013 to 2022

Registry Committee

- APBMT Registry Committee
 - About Activity Survey
 - About Outcome Registry
- Registry Committee Member List

Nuclear Accident Management (NAM) Committee

- NAM Committee Activities and Member List

Executive Board

- Executive Board Activities
- Executive Board Members

Collaboration with Other International Registries

- General Information
- History of International Scientific Symposia

Blood Cell Therapy -The Official Journal of APBMT-

- About the Journal
- Editorial Board Member List
- List of the Accepted Articles (Volume 5.)

Appendix

- Cooperate Members

Introduction

General Overview 2022

All 22 of APBMT's participating countries/regions are listed here. (As of December 2022)

Australia
Bangladesh
Cambodia
China
Hong Kong
India
Indonesia
Iran
Japan
Korea
Malaysia
Mongolia
Myanmar
Nepal
New Zealand
Pakistan
Philippines
Singapore
Sri Lanka
Taiwan
Thailand
Vietnam



This Annual Report is the 15th edition overall and the second edition following our transition to this new digital format. It includes APBMT activities from January to December in 2022. Though the COVID-19 pandemic continued to powerfully influence to the medical field of HSCT in this region throughout the year, all doctors and medical personnels made a great effort to care for patients with hematological diseases and we have started new cellular therapy including CAR-T treatment in many countries/regions. The 27th annual congress was held in Kochi, India on the hybrid platform and it was a great success that many participants actually came to the place and we had lively discussions and presentations with other virtual participants.

This Annual Congress was operated following the new guidelines for hosting the congress which was approved in 2021 and was successfully closed in partnership with APBMT headquarter and host country.

Please note that, you can find the results of the Activity Survey on APBMT website:

<https://www.apbmt.org/research/registry/survey>

BYLAWS OF THE ASIA PACIFIC BLOOD AND MARROW TRANSPLANTATION GROUP (APBMT)

ARTICLE 1

Name of the Group

The Asia Pacific Blood and Marrow Transplantation Group, hereafter referred to as APBMT was established in 1990 to allow doctors, other health professionals and scientists in the Asia Pacific region involved in clinical blood and marrow transplantation and therapies related to hematopoietic stem cell transplantation to collaborate and promote high quality blood and marrow transplantation in the region.

ARTICLE 2

Incorporation

APBMT is incorporated as Corporate Juridical Person for scientific and educational purposes under the laws of Japan.

ARTICLE 3

Purpose of APBMT


The group aims to promote all aspects associated with the hematopoietic stem cell transplantation (HSCT) and related therapies in the Asia Pacific region, which includes:

- To ascertain and provide the updated status of haematopoietic stem cell transplantation (HSCT) in the Asia Pacific region.
- To steer and regulate the HSCT Registry in the Asia Pacific region (Asia Pacific Blood and Marrow Transplantation Group Registry: APBMT Registry)
- To share current knowledge of all aspects of HSCT to promote and maintain the highest standards of care, and to work towards a set of standards and accreditation of transplant units.
- To provide training opportunities in HSCT in the Asia Pacific region.
- To promote collaborative research in the Asia Pacific region.
- To collaborate with other international organizations related with HSCT
- To work as a core voting member of WBMT

ARTICLE 4

Organization

The schema of the organization in APBMT indicates below.



4. Membership Any persons involved in the treatment of recipients and donors (such as physicians, nurses, laboratory technicians, persons related to stem cell donor programs or pharmaceutical companies), who are involved in HSCT and agree with the purpose of the group can become a member (see above section). New members are admitted by submitting a membership application form and CV up to 2 pages to the Secretary Office. This application must include the signature of an APBMT member as a presenter. There are two different kinds of memberships; Scientific members (physicians, nurses, laboratory technicians, persons related to stem cell donor programs) and Corporate members (pharmaceutical and for-profit companies). Scientific members include Regular, Associate, Affiliate, Honorary and Emeritus members. All members have to pay annual membership fees except for the Honorary and Emeritus members.

4.1 Regular members

Regular members consist of members from medical fields with an M.D. or Ph.D sufficient experiences and demonstrated in hematopoietic stem cell transplantation / cellular therapy. A proposed new member must provide a membership application form and CV that includes professional qualification, work experiences, current employment and place of work to the Secretariat Office. Regular members must agree to abide by the regulations of APBMT, to participate in scientific endeavors of APBMT, to have good ethical and moral standards as well as no criminal record, as expected by professional societies. Regular members can attend the Business meeting but do not have voting right. Regular members can elect and can be elected as Scientific Committee members within each country.

4.2 Associate members

Individuals with and M.D. or Ph.D who do not meet the criteria for regular membership will become Associate members. Associate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.3 Affiliate members

Professionals who are members of HSCT / cellular therapy team or interested in HSCT / cellular therapy (NP, PA, Pharm D, RN etc.) are eligible to be Affiliate members. Affiliate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.4 Emeritus members

Anyone in APBMT who has contributed in a significant way to its development is eligible to become Emeritus Members. Emeritus members are nominated by the Executive Board and are approved by the Scientific Committee at the business meeting. Emeritus Members are eligible to participate in the business meeting.

4.5 Honorary members

Individuals who are not an APBMT member but have contributed to the establishment or the development of APBMT are eligible to become an Honorary member. Honorary members are nominated by the APBMT members and are approved by the Scientific Committee at the business meeting. Honorary

members are ineligible to participate in the Business meeting.

4.6 Corporate members

Representatives of commercial and for-profit companies can become Corporate members. Corporate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.7 Scientific Committee

Scientific Committee is the supreme decision-making body in APBMT. Each country can elect and nominate 1 voting member as the country representative. The vote is casted by the country representative but this right may be transferred to a designated substitute. If there is more than one nominee from one country, the Scientific Committee can vote to select one candidate. The names of the current members of scientific committee are listed and updated annually. The Chairman of the Executive Board, who also serves as the Chairman of the Scientific Committee, has the deciding vote if the vote is otherwise tied.

New Scientific Committee members need to be recommended by the current members of Scientific Committee among the members of the Regular Members and to get approval in the business meeting. Decisions are taken by majority voting (One vote/one country). A proposed new member must provide a brief CV up to 3 pages. The criteria to be a Scientific Committee Member include proven medical and/or scientific experience in HSCT; willingness to committee and participate in scientific endeavors of APBMT; no criminal record, good ethical and moral standards as expected by professional societies.

The Scientific Committee member has the following rights and obligations: 1) To attend the Annual Business Meeting; 2) To elect Executive Board members; 3) To decide on admission of new members; 4) To decide the annual fee for APBMT membership; 5) To make final decision on APBMT policies and its finance.

A Scientific Committee member will lose his/her rights as a representative of his/her country/region when he/she leaves his/her original country/region permanently.

4.8 Executive Board

The Executive Board of APBMT steers the group for administration and all decisions that need to be taken for functioning of the organization in accordance

with the constitution and bylaws of the organization. The Executive Board is responsible for all running operations and decisions that are not due to be taken by the Scientific Committee at the annual meeting. The Executive Board, appointed by the Scientific Committee, will act on behalf of all members for regular decisions during the period between Scientific Committee meetings. During this period, the Scientific Committee need not be consulted unless a decision would affect the bylaws or contravene a decision previously made by the Scientific Committee. The Executive Board consisted of regular members (only one member permitted from one country) elected from the Scientific Committee. The maximum number of members of the Executive Board is nine. The Chairman of Executive Board represents APBMT.

4.9 Officers of the Executive Board

1. Scientific Committee elects a) one Chairman of Executive Board, b) one Vice Chairman of Executive Board, c) several other Members of Executive Board including one Secretariat / Treasurer. The members of the Executive Board are elected by the business meeting, and serves for two years and may be re-elected for another term of two years.
2. The function of the Chairman of Executive Board is to promote and coordinate all activities of APBMT. These include fund raising, coordination of Working Group activities, giving suggestions to the organizers of the annual meeting, and negotiations with other organizations on behalf of APBMT.
3. The Vice Chairman supports the Chairman and will perform the duties of the Chairman in the absence.

4.10 Secretariat/Treasurer

Secretariat / Treasurer shall oversee the maintenance of a permanent record of APBMT. The Secretariat / Treasurer shall have oversight of the budget of APBMT. The Secretariat / Treasurer Office works for the development and the maintenance of the group under the collaboration with the Chairman of Executive Board, the Chairman of the next annual congress, and the members of Executive Board and Scientific Committee.

ARTICLE 5

Committees and Working Groups

5.1 Committees

APBMT will have the following Standing Committees to help with its work.

1. Membership Committee
2. Registry Committee
3. Program Committee
4. Nuclear Accident Management (NAM) Committee
5. Editorial Board of the Blood Cell Therapy, the Official Journal of APBMT

Each of these committees will have a specific term of reference.

5.2 Working Groups

The aim of Working Groups is to enhance research in focused areas. The Executive Board and Scientific Committee of APBMT determine the formation of Working Groups as required. The application of the new Working Group and its chair person is approved by the members of the Scientific Committee in the Business Meeting (see Annex). The chair person of each Working Group is elected for three years and may stand for reelection once. The substructure of the Working Group is defined by the chair person in consultation with the Executive Board. Regular Members are encouraged to participate in one or more Working Groups according to their particular interests. The Working Group chair person must submit annual activity reports to the Scientific Committee and the Executive Board. The chairperson should adhere to the Working Group responsibilities, which are specified separately from the bylaws.

ARTICLE 6

Meetings

6.1 Annual Congress

Any countries participating in APBMT can propose to be a host country of the Annual Congress. Host country of the future Annual Congresses will be decided by the Scientific Committee. The President of the next annual congress cooperates with the Executive Board for the year preceding the annual congress. The format of the meeting is to be standardized (see Annex section below).

6.2. Business Meeting

The Scientific Committee will open the Business Meeting at least once a year. One of them will be held during the annual meeting. It is co-chaired by the Chairman of the Executive Board and the President of the Annual Congress. The Board may establish subcommittee / working party as the need arises.

6.3 Board Meeting

The Executive Board of the APBMT shall meet in person at the annual meeting. It is presumed that all members will attend this meeting unless there are unavoidable personal circumstances. In addition, the board will meet via conference calls every 4-8 weeks, as needed. All members are expected to attend all scheduled board meetings.

ARTICLE 7

7.1 APBMT Registry

A major activity of the APBMT will be to guide the development of national registries in each country. This data will then be collected into the combined APBMT registry in formats compatible with other international registries. Both activities and outcome data will be collected every year.

7.2 Annual Report

The list of registrants and summary of analyses are published in the APBMT Annual Report of each year, which is distributed to the APBMT member and related persons / organizations. The results published in the APBMT Annual Report is confidential, however, it can be quoted after written approval from APBMT and accompanied by proper acknowledgement.

7.3 Rules on the use of the Registry data

Data are restricted to publication in a scientific article and / or presentation at academic meetings. APBMT contributions must be appropriately acknowledged in all presentations and publications prior to the release of the data and analyses. Written Applications for these purposes are limited to Scientific Committee Members, Working Groups and the Data Center of APBMT for the time being. Written requests from other academic organizations or commercial companies will be assessed and if approved a cost recovery will be charged depending on the amount of work. Confidentiality of source information will be protected in accordance with the laws of individual centres and countries. An application form is attached as a separate sheet. The Registry Committee will evaluate all applications and approval made after consultation with the Executive Board.

ARTICLE 8

Finance

8.1 Membership Fees:

All the Regular Members are required to pay annual membership fees on an individual basis (see Annex). The members who paid the membership fees can receive up-to-date information including the survey data from APBMT office and also may have the advantage of discount of the registration fees at annual congress.

8.2 Statement of accounts of annual APBMT congress

An audited statement of accounts must be prepared by the organizing committee for each annual APBMT meeting within one year of its completion and submitted to the APBMT Headquarters and presented at the annual business meeting.

ARTICLE 9

Amendments

9.1 These Bylaws may be amended at any annual business meeting of the Scientific Committee Amendments to the Bylaws may be proposed in writing to the Executive Board and must be submitted at least ninety days prior to the annual meeting. In addition, the Executive Board may initiate proposed amendments to the Bylaws.

The proposed amendments, together with the Executive Board's recommendation, shall be distributed to members of the Scientific Committee at least thirty days before the annual meeting at which it is to be considered. To be adopted, an amendment must be approved by at least two thirds of voting at the annual meeting.

9.2 Annexures may be amended by the Executive Board, (with a minimum of two third majorities of the members of the Executive Board) and report to the Scientific Committee.

Annexures:

1. Committees - Terms of Reference to be determined.
2. Working Groups - Terms of Reference to be determined.
3. Annual Congress – Format of the meeting to be formulated
4. The APBMT Registry
5. Financial Issues

6. The Scientific Committee members: In addition to the criteria to be a Scientific Committee Member described in APBMT Bylaw (4.7 Scientific Committee), the candidate must have served as a regular member for the past three years with the consecutive payment of annual membership fee. No term limits are set for Scientific Committee Members. However, the members are required to participate in at least 2 out of 4 most recent APBMT Annual Congress, and consecutively pay annual membership fee in order to maintain their membership. In addition, their willingness of serving as Scientific Committee Members is to confirm every two years. No limits are set for the maximum number of Scientific Committee members in each country/region participating APBMT

7. Others

(Detailed rules such as payments and duties for the members are described in the annexure)

Establishment: October 1, 2009

History of revision:


December 31, 2010

October 31, 2015

November 1, 2016 (Annexure 6 was added.)

August 31, 2019

Organizational Tree of APBMT



Principal Member List

Executive Board members

Shinichiro Okamoto (Chairman, Japan)	Alok Srivastava (Vice-chair, India)	David D Ma (Australia/New Zealand)
He Huang (China)	Amir Ali Hamidieh (Iran)	Jong Wook Lee (Korea)
William YK Hwang (Singapore)		

*Scientific Committee Members (*Executive Board members)*

Yoshiki Akatsuka (Japan)	Otgonbat Altangerel (Mongolia)	Shashikant Apte (India)
Khishigjargal Batsukh (Mongolia)	Carmella Bingcang (Philippines)	Pheng Bora (Cambodia)
Udomsak Bunworasate (Thailand)	Tzeon-Jye Chiou (Taiwan)	Sharat Damodar (India)
Gin Gin Gan (Malaysia)	Lallindra Gooneratne (Sri Lanka)	Aye Aye Gyi (Myanmar)
Amir Ali Hamidieh (Iran) *	Suradej Hongeng (Thailand)	He Huang (China) *
Xiao-Jun Huang (China)	Tai-ju Hwang (Korea)	William YK Hwang (Singapore) *
Hyoung Jin Kang (Korea)	Mohiuddin Khan (Bangladesh)	Navin Khattry (India)
Bor-Sheng Ko (Taiwan)	Mickey Koh (Singapore)	Hoon Kook (Korea)
Hsiao Liang-Tsai (Taiwan)	Jong Wook Lee (Korea) *	Albert Lie (Hong Kong)
Kai-Hsin Lin (Taiwan)	Kai-yan Liu (China)	David D Ma (Australia/New Zealand) *
Koichi Miyamura (Japan)	John Moore (Australia/New Zealand)	Shinichiro Okamoto (Japan) *
Jian Ouyang (China)	Chi Dung Phu (Vietnam)	Bishesh Sharma Poudyal (Nepal)
Damai Santosa (Indonesia)	Tahir Sultan Shamsi (Pakistan)	Alok Srivastava (India) *
Jih-Luh Tang (Taiwan)	Shuichi Taniguchi (Japan)	Takanori Teshima (Japan)
Artit Ungkanont (Thailand)	Auro Viswabandya (India)	Jianmin Wang (China)
Jong-Ho Won (Korea)	Tong Wu (China)	Mei Zhang (China)

Honorary Members

Kerry Atkinson (Australia)	John Carter (New Zealand)	Dennis Confer (NMDP)
John Goldman (EBMT)	Alois Gratwohl (EBMT)	Geoffrey Hill (Australia)
Mary Horowitz (CIBMTR)	Dietger Niederwieser (EBMT)	

Emeritus Members

Suresh H Advani (India)	Shigetaka Asano (Japan)	Lu Xian Cao (China)
Po-Min Chen (Taiwan)	Ardeshir Ghavamzadeh (Iran)	Surapol Issaragrisil (Thailand)
Saengsuree Jootar (Thailand)	Chun Choo Kim (Korea)	Dong Jip Kim (Korea)
Yoshihisa Kodera (Japan)	Dao-Pei Lu (China)	Tohru Masaoka (Japan)
Tan Binh Nguyen (Vietnam)	Philip Rowlings (Australia/New Zealand)	Tapan K Saikia (India)
Patric Tan (Singapore)	Ming Yao (Taiwan)	

Annual Congresses

Guidelines for the hosting of the APBMT annual congress

Planning and preparation

- APBMT Annual Congress is organized by APBMT in collaboration with the host country/society each year through an Organizing Committee and a Scientific Program Committee (SPC).
- The chair of the APBMT Board will be a Co-President of the Annual Congress along with a Co-President nominated by the host country.
- Both committees will function as per a schedule drawn up by the APBMT Secretariat for targets to be achieved to the dates of the congress.
- The Organizing Committee will have two Co-chairs - Chair of the APBMT Board/Board nominee with a Co-chair from the host country/society, and the equal number of members nominated by the APBMT Board and the host country/society.
- The Scientific Program Committee (SPC) of Congress will have two co-chairs - one local and one APBMT Executive Board (EB) nominated along with an equal number of local and EB nominated international members.

The scientific program will be planned according to the standard format:

- 1st day for APBMT standing committees and working group meetings- Industry symposia / CME program or educational symposia followed by 2 ½ days of the scientific program.
- The program should consist of three major tracks for physicians, nurses, and other specialists (such as laboratory diagnostics, cell and graft manipulation, pharmacists)
- The program should contain both educational sessions and sessions covering recent topics/advances in hematopoietic cell transplantation and related fields.
- Each session has a theme on which there could be 3-4 talks in up to 90min.
- The speakers of each topic should be decided by SPC with the invitation letters to be sent by the Co-Chairs of SPC.
- Try to recruit speakers from APBMT participating countries/regions as much as possible (at least 50%) – giving representation to as many countries from Asian-Pacific (AP) regions AP as possible. Criteria for selection of speakers to be defined and followed.
- No AP country/region should have more than 10% of the total number of speakers from Asian Pacific regions in the entire Scientific Program; however, it is acceptable for a host country to have more speakers depending on their suitability but not exceeding 20% of the total.

- The term “speaker” here is determined as the one listed in the Scientific Program (including Plenary and Educational Session) prepared by the SPC but excluding sponsored symposia.
- The meeting should be organized as a hybrid meeting but with major emphasis on a physical meeting when circumstances permit.

Funding

- APBMT office may directly collect funding support from the international division of a multinational company (MNC), and the local host country will collect the support from domestic divisions of MNCs / local companies.
- The overall cost of hosting the Annual Congress will be shared between APBMT and the host country in the same proportion as the total funds collected from all sources.
- Left over funds after meeting all costs of the Annual Congress will be shared between APBMT and the host country in the same proportion as the overall fund collected.
- The budget for the Annual Congress should therefore be jointly decided between APBMT and the host country through the Organizing Committee and the Co-Presidents.

After the congress

- The hosting country must submit the followings to APBMT Secretariat after the meeting
 - Generate and report the financials
 - Submit a list of all attendees (names, countries and email address if possible)
 - Provide all abstracts for uploading on the Blood Cell Therapy website. The permission should be obtained from presenters when they were submitted
 - Provide photos and PowerPoint presentations made during the Congress for uploading the APBMT website after due permissions from the speakers.

Previous Congresses

No	Year	City	Presidents
1 st	1990	Beijing	Lu Xian Cao
2 nd	1991	Nagoya	Tohru Masaoka
3 rd	1992	Osaka	Tohru Masaoka
4 th	1994	Fukuoka	Tohru Masaoka
5 th	1996	Seoul	Dong Jip Kim
6 th	1998	Taipei	Yao-Chang Chen
7 th	2000	Bangkok	Surapol Issaragrisil
8 th	2002	Mumbai	Suresh Advani
9 th	2004	Tehran	Ardeshir Ghavamzadeh
10 th	2005	Hangzhou	Dao-Pei Lu
11 th	2006	Nagoya	Yoshihisa Kodera
12 th	2007	Beijing	Dao-Pei Lu
13 th	2008	Taipei	Po-Min Chen
14 th	2009	Seoul	Chun-Choo Kim
15 th	2010	Phuket	Saengsuree Jootar
16 th	2011	Sydney	David Ma / Philip Rowlings
17 th	2012	Hyderabad	Tapan K Saikia / Alok Srivastava
18 th	2013	Ho Chi Minh City	Tan Binh Nguyen
19 th	2014	Hangzhou	He Huang / Xiaojun Huang
20 th	2015	Okinawa	Shinichiro Okamoto
21 st	2016	Singapore	William YK Hwang / Chng Wee Joo / Aloysius Ho
22 nd	2017	Tehran	Ardeshir Ghavamzadeh
23 rd	2018	Taipei	Ming Yao / Jih-Luh Tang
24 th	2019	Busan	Jong Wook Lee / Jong-Ho Won
25 th	2020	APBMT/ISBMT (Virtual)	Mammen Chandy
26 th	2021	Chiang Mai (Hybrid)	Artit Ungkanont
27 th	2022	Kochi (Hybrid)	Alok Srivastava

Future Congresses

- The 28th Annual Congress
Oct. 26 (Thu) - Oct. 29 (Sun), 2023
Semarang, Indonesia
Congress President: Damai Santosa

The Number of Attendees for Each Annual Congress from 2013 to 2022


2013(VIETNAM)		2014(CHINA)		2015(JAPAN)		2016(SINGAPORE)		2017(IRAN)	
Vietnam	375	China	646	Japan	159	Singapore	234	Iran	565
China	82	Japan	31	China	186	China	116	China	32
Korea	41	Taiwan	24	Taiwan	51	Japan	62	USA	4
Japan	32	Korea	16	Korea	41	Korea	44	Germany	4
Taiwan	17	United States	11	Singapore	23	Taiwan	28	Japan	3
Thailand	13	India	9	Hong Kong	17	India	25	Thailand	3
Hong Kong	7	Singapore	9	Vietnam	16	USA	22	Qatar	3
Belgium	6	Australia	7	India	11	Thailand	21	France	2
Singapore	6	Mongolia	7	Thailand	11	Hong Kong	19	Italy	2
France	5	UK	5	Indonesia	9	Malaysia	19	Belgium	1
India	5	Hong Kong	4	USA	7	Bangladesh	15	India	1
Australia	4	Philippines	4	Malaysia	6	Vietnam	15	Turkey	1
Iran	4	Vietnam	4	Australia	5	Australia	13	UK	1
United States	4	France	3	Philippines	5	Iran	11	Malaysia	1
Germany	3	Iran	3	UK	4	Philippines	10	Sri Lanka	1
Mongolia	3	Thailand	3	Germany	2	Germany	9	Switzerland	1
Spain	3	Germany	2	Iran	2	Sri Lanka	6	Total	625
Malaysia	2	Myanmar	2	Sri Lanka	2	UK	6		%
Philippines	2	Pakistan	2	Bangladesh	1	France	4	Domestic	90
Indonesia	1	Bangladesh	1	Cambodia	1	Mongolia	4	Foreign	10
Ireland	1	Indonesia	1	Canada	1	Indonesia	3		
Myanmar	1	Lebanon	1	France	1	Ireland	3		
Netherlands	1	Malaysia	1	Italy	1	Italy	3		
Sweden	1	South Africa	1	Mongolia	1	Cambodia	2		
UK	1	Spain	1	Myanmar	1	Myanmar	2		
Total	736	Sri Lanka	1	Pakistan	1	Qatar	2		
	%	Total	799	Switzerland	1	Belgium	1		
Domestic	61		%	Missing	1	Canada	1		
Foreign	40	Domestic	81	Total	567	Nepal	1		
		Foreign	19		%	New Zealand	1		
				Domestic	28	Spain	1		
				Foreign	72	Switzerland	1		
						Total	704		
							%		
						Domestic	33		
						Foreign	67		

2018(TAIWAN)		2019(KOREA) ※		2020(INDIA) ※ ※		2021(THAILAND) ※ ※ ※		2022(INDIA) ※ ※	
Taiwan	330	Korea	762	India	822	Thailand	525	India	446
China	90	China	125	China	173	Singapore	48	Singapore	19
Japan	66	Japan	47	Philippines	98	Japan	31	Vietnam	19
Korea	33	Taiwan	46	Vietnam	68	China	26	Japan	16
Singapore	32	India	37	Japan	67	India	18	Thailand	7
Vietnam	29	Indonesia	22	Singapore	36	Hong Kong	17	Hong Kong	5
Thailand	21	Singapore	22	Korea, South	28	Malaysia	17	Indonesia	5
Hong Kong	18	Malaysia	17	Burma	27	Australia	11	Austria	4
USA	15	USA	17	Iran	26	Bangladesh	11	China	4
Philippines	13	Vietnam	16	Malaysia	23	Vietnam	11	Malaysia	4
India	11	Germany	11	Australia	21	Philippines	10	USA	5
Malaysia	8	Hong Kong	10	Thailand	20	USA	9	Pakistan	3
Indonesia	7	Thailand	9	Bangladesh	17	UK	8	South Korea	3
Australia	6	Iran	8	Pakistan	16	Indonesia	7	Spain	3
Bangladesh	6	Mongolia	8	Saudi Arabia	12	Korea	7	Germany	2
Sri Lanka	5	Pakistan	8	United Kingdom	12	Taiwan	5	Iran	2
UK	5	Philippines	7	Taiwan, China	11	Germany	4	Poland	2
Germany	4	Australia	5	United States	10	France	2	Taiwan	2
Canada	3	Egypt	3	Germany	9	México	2	Brazil	1
Mongolia	3	France	3	Sri Lanka	9	Argentina	1	Canada	1
Myanmar	3	Turkey	3	Hong Kong, China	8	Austria	1	Israel	1
Romania	2	UK	3	Indonesia	6	Canada	1	Italy	1
Cambodia	1	Switzerland	2	Mongolia	6	Iran	1	Jordan	1
France	1	Spain	2	Canada	4	Italy	1	Myanmar	1
Iran	1	Bangladesh	2	France	3	Myanmar	1	Philippines	1
Netherlands	1	Austria	1	Italy	2	Pakistan	1	Sri Lanka	1
North Korea	1	Brazil	1	Nepal	2	Portugal	1	Total	559
Spain	1	Cambodia	1	Belgium	1	UAE	1		%
Total	716	Canada	1	Cambodia	1	Total	778	Domestic	80
	%	Italy	1	Ireland	1		%	Foreign	20
Domestic	46	Myanmar	1	Netherlands	1	Domestic	67		
Foreign	54	Nepal	1	Sweden	1	Foreign	33		
		Netherlands	1	Switzerland	1				
		Poland	1	United Arab Emirates	1				
		Sri Lanka	1	Total	1543				
		Uzbekistan	1		%				
		Total	1206	Domestic	53				
		%		Foreign	47				
		Domestic	63						
		Foreign	37						

*APBMT 2019 with ICBMT 2019 (International Congress of Blood and Marrow Transplantation)

**APBMT 2020&2022 with ISBMT (Indian Society for Blood & Marrow Transplantation)

***APBMT 2021 with TSH (Thai Society of Hematology)



Registry Committee

APBMT Registry Committee

APBMT has long collected HSCT activity and outcome data through APBMT Data Center. To promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014 and it officially started operations in October 2015. APBMT Data Center was integrated into the Committee. In 2022, the Committee established the Task Force for Activity Survey Form Revision and accomplished the following:

- Revise the APBMT disease classification table
- Split the survey form between adults and children (from the 2021 survey)
- Finalize the survey form for the Cellular Therapy (be planned to start in 2022)


Tasks for the Committee:

- Perform the annual APBMT Activity Survey and Outcome Registry
- Support data collection in participating countries/regions
- Manage and analyze the collected data
- Optimize the data usage
- Support clinical researches using collected data
- Collaboration with other societies for research

[About Activity Survey]

The APBMT Activity Survey has been performed annually since 2007 (HSCT data from 2005). This survey collects the number of transplantations sorted by the donor sources and diseases in each country/region.

The following figure shows how the data is collected.



The method of submission is different in each country/region.

As shown in the figure above, data from China, India, Japan, Korea, Malaysia, and Taiwan was submitted through their respective national registry. Data in Iran was submitted from the Ministry of Health. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Indonesia, Myanmar, the Philippines, Sri Lanka, and Thailand, data was collected by a designated contact person and submitted to Data Center. Data Center has direct contact with significant transplantation centers and receives data from Hong Kong, Mongolia, Nepal, Pakistan, Singapore, and Vietnam. Data Center compiles all data collected in each of these six countries/regions, and gathered data is available for each country/region to use as national data.

The results of the Activity Survey can be found on the APBMT website:

<https://www.apbmt.org/research/registry/survey>


[About Outcome Registry]

APBMT Registry Committee and Data Center have been collecting the HSCT outcome

data of each patient. The basic dataset structure is called the Least Minimum Dataset (LMD), and three methods are available for sending data to Data Center depending on the situation in each country/region.

- The simplified Excel forms made by APBMT Data Center based on the EBMT MED-A or the CIBMTR TED
- Receiving data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR
- The electronic data capture (EDC) system using REDCap®

When the Registry/Society in participating counties/regions starts to submit HSCT outcome data to APBMT, a Non-Disclosure Agreement (NDA) is signed between APBMT and the Registry/Society when requested. In addition, APBMT Registry Committee stipulates detailed rules for data usage so that the submitted data will not be disclosed without the consent of the Committee.



*The following countries/regions are building up their systems for submitting outcome data: China, Iran, Korea, and Thailand.

Registry Committee Member List

	Name	Country/Region
Chairperson	Yoshiko Atsuta	Japan
Deputy Chairpersons	Anthony Dodds	Australia/New Zealand
	Aloysius Ho	Singapore
Members	Mafruha Akter	Bangladesh
	Pheng Bora	Cambodia
	Xiao Jun Huang	China
	Liu Kaiyan	China
	Lv Meng	China
	Joycelyn Sim	Hong Kong
	Vincent Lee	Hong Kong
	Alok Srivastava	India
	Kavitha M.L	India
	Damai Santosa	Indonesia
	Amir Hamidieh	Iran
	Shinichiro Okamoto	Japan
	Yachiyo Kuwatsuka	Japan
	Joon Ho Moon	Korea
	Kim Wah Ho	Malaysia
	Batsukh Khishigjargal	Mongolia
	Aye Aye Gyi	Myanmar
	Bishesh Poudyal	Nepal
	Tasneem Farzana	Pakistan
	Marjorie Rose Bravo	Philippines
	Prasad Abeysinghe	Sri Lanka
	Devinda Jayathilake	Sri Lanka
	Bor-Sheng Ko	Taiwan
	Hui-Fen Chiang	Taiwan
	Po-Nan Wang	Taiwan
	Ming Yao	Taiwan
	Artit Ungkanont	Thailand
	Suradej Hongeng	Thailand
	Huynh Van Man	Vietnam
	Phu Chi Dung	Vietnam
Data Center	Minako Iida	Japan
	Yukari Nakao	Japan
	Hiroe Namizaki	Japan

Nuclear Accident Management (NAM) Committee

Nuclear Accident Management (NAM) Committee

The APBMT Nuclear Accident Management Committee (NAM Committee) was established at the APBMT Annual Congress in Hyderabad, India, in 2012 to:

- 1) investigate what is happening in this region and what is being done around the world in the field of a nuclear accident
- 2) facilitate cooperation with other societies such as EBMT, ASTCT, and WBMT
- 3) establish an APBMT Nuclear Accident Registry
- 4) establish a training program
- 5) prepare the standard operating procedure for the handling of the nuclear accident in our region

Since then, the NAM meeting has been held every year at the Annual Congress, and the final draft of the NAM guidelines, written by co-chairs (Drs. Velu Nair and Hyo Rak Lee), was approved by the APBMT Scientific Committee in 2020.

<https://www.apbmt.org/education/guideline-nam>

Member List

Position	Name	Country/Region
Chair	Velu Nair	India
Chair	Hyo Rak Lee	Korea
Past Chair	Alok Srivastava	India
Past Chair	David Ma	Australia
	Mohiuddin Khan	Bangladesh
	Koichi Miyamura	Japan
	Syuuichi Taniguchi	Japan
	Khishigjargal Batsukh	Mongolia
	Aye Aye Gyi	Myanmar
	Simit Sapkota	Nepal
	Prasad Abeysinghe	Sri Lanka
	Phu Chi Dung	Vietnam
Chair, Executive Board	Shinichiro Okamoto	Japan

Executive Board

Executive Board Activities

For smooth management of the international society, executive board members have official web conferences every month and ad-hoc web conferences as necessary.

The main topics discussed in the Executive Board web conferences:

- Preparation of the Annual Congress in collaboration with the host country/region
 - Making up the scientific program
 - Nomination of speakers
 - Management of funding
- Nominating the host country/region for the upcoming annual congress
- Expansion of membership, including the EB members.
- Sponsorship contracts with the third parties/companies
- Collaboration with ASTCT, EBMT, WBMT, and other related societies in the field of HSCT
- Membership control
 - Review of membership application forms
 - Membership fees
 - Dual membership with ASTCT
- Solving the problems with advice to each committee (Registry Committee, Editorial Board of Blood Cell Therapy, Financial Committee)
- Conduct survey research if necessary
 - Antiemetics (Nutrition Support Working Group)
 - Access to HCT and Cellular Therapy
 - Activity of Cancer Immunology in Asian Countries

Executive Board Members



Shinichiro Okamoto
Chairman
Japan



Alok Srivastava
Vice Chairman
India



Jong-Wook Lee
Korea



David Ma
Australia



Amir Hamidieh
Iran



William Hwang
Singapore



He Huang
China

Collaboration with Other International Registries

WBMT

ASTCT

EBMT

WBMT (Worldwide Network for Blood & Marrow Transplantation)

APBMT is one of the founding societies of WBMT and has collaborated with other member societies such as CIBMTR, EBMT, and WMDA to operate WBMT since 2007.

Dr. Yoshihisa Kodera (Japan) and Dr. Jeff Szer (Australia) have served as president of WBMT. Many members in APBMT played important roles in the Standing Committees in 2020, with Yoshihisa Kodera acting as Co-chair of the Education & Dissemination Committee and Yoshiko Atsuta serving as Co-chair of the Transplant Centre/Recipient Committee.

In addition, APBMT Data Center has submitted the Activity Survey data every year to contribute to the WBMT Global Transplant Activity Survey.

ASTCT (American Society for Transplantation and Cellular Therapy)

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership. APBMT members who applied for this membership could receive many benefits from ASTCT. APBMT and ASTCT will continue to collaborate in the future.

EBMT (European Society for Blood and Marrow Transplantation)

APBMT has been collaborating with EBMT on many projects for a long time (booth set up at the EBMT annual meeting, advice from the JACIE members to formulate the APBMT Center Standards, the nomination of speakers for EBMT-sponsored webinars, etc.) APBMT receives valuable advice from EBMT on managing the society, and we will continue working together.

History of International Scientific Symposia

2022

October, APBMT 2022 hybrid (India)

Presidential Symposium: Activity and Regulation of Cellular Therapies

Chairpersons: S. Okamoto, A. Srivastava

- EBMT perspective (A. Sureda)
- ASTCT perspective (M. Perales)
- WBMT perspective (D. Niederwieser)
- APBMT perspective (S. Okamoto)

February, WBMT 2021 hybrid (Pakistan)

Quality Assurance in HSCT Centers

Chairpersons: A. Seber, T. Mahmood Satti

- Overview and principles of quality systems in HSCT centers (A. Alseraihy)
- How to get an HSCT program accredited? (S. Okamoto)
- Where do we first start? From following standards to successfully obtaining accreditation (A. Kondo)

February, WBMT 2021 hybrid (Pakistan)

Patient/Donor Registration and Outcome Database

Chairpersons: Y. Atsuta, F. Alfraih, M. Ayaz Mir,

- The value of a transplant activity survey (H. Baldomero)
- The value of outcome databases (M. Pasquini)
- The APBMT Registry (M. Iida)

2021

October, APBMT 2021 hybrid (Thailand)

Presidential Symposium: Design the future of HCT Societies

Chairpersons: S. Okamoto, A. Ungkanont

- EBMT perspective (N. Kroger)
- ASTCT perspective (S. Davies)
- WBMT perspective (H. Greinix)
- APBMT perspective (S. Okamoto)

July, FACT/WBMT Webinar

Quality and Accreditation for Cellular Therapy: A Global Perspective

- Establishing an HSCT Program: Essential Requirements (D. Niderwieser)

- Development of a Quality Program in the Asia-Pacific Region (A. Srivastava)
- FACT-JACIE Accreditation in Latin America (C. Bachier)

June, EBMT Summit on COVID-19

Clinical Impact and management in HSCT patient 1, Activity impact and clinical outcome

Chairs: P. Ljungman, M. Mikulska

- EBMT experience (P. Ljungman)
- USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center (G. Papanicolau)
- Asian Pacific BM Society experience (APBMT) (W. Hwang)

April, WBMT/EBMT Webinar

Haplo-Identical HSCT, Methods and Practices Around the Globe

Moderators: H. Greinix, N. Kröger

- Haploidentical HSCT practice in Europe (A. Bacigalupo)
- Haploidentical HSCT practice in Asia (XJ. Huang)
- Haploidentical HSCT practice in North America (L. Luznik)

March, EBMT (virtual)

Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics

Co-Chairs: N. Kröger, S Davies, M. Riches, A. Srivastava

- US Experience: Pandemics and Transplantation/Cell therapy (A. Waghmare)
- The CIBMTR COVID Experience: Challenges for research and how COVID has changed transplant practice (M. Riches)
- The IDWP-EBMT COVID 19 Experience (R. Cámara)
- Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment during COVID 19 pandemic (Y. Hu)

February, ASTCT (Digital Experience)

WBMT Concurrent: Transplant During a Worldwide Crisis: Lessons Learned Across the World

Co-Chairs: W. Saber, M. Aljurf

- The Latin American Bone Marrow Transplantation Group (LABMT) Experience (A. Seber)
- HSCT Challenges and Solutions Under COVID-19: The Experience from China (X. Huang)
- The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group Experience (RE. Fakih)

2020

October, APBMT 2020 virtual (India)

Presidential Symposium on HSCT and Covid-19

Chairpersons: S. Okamoto, N. Kroeger, A. Srivastava

Moderator: S. Damodar

- HSCT in the Covid-19 Era- the Chinese Experience (H. Huang)
- Practice of HSCT in North America in COVID-19 Era (N. Majhail)
- Practice of HSCT in Europe in COVID-19 Era (P. Ljungman)
- Managing HSCTs in the context of COVID-19 pandemic - A LMIC perspective (S. Damodar)

May, WBMT Live Webinar (Online)

COVID-19 and stem cell transplantation, a Worldwide perspective:

Moderators: Y Kodera, S Galeano

- Management of donors during the pandemic (F. Alfraih)
- Transplant recipients; COVID-19 guidelines and real-world (C. Machado)
- Chinese experience (H. Huang)
- Data from the EBMT registry during COVID-19 (P. Ljungman)
- Chimeric Antigen Receptor T Cell Therapy during COVID-19 (MA. Perales)

2019

August, APBMT (Korea)

ASTCT/EBMT/WBMT/APBMT Joint Session:

Co-Chairs: JW Lee, S. Okamoto

- GvHD Prophylaxis with Post Cy after Haplo-Identical, Matched Unrelated and HLA-Identical Sibling Transplantation (N. Kroger)
- Future Changes in Stem Cell Transplantation and Cellular Therapy: Safer, Less Toxic and Less Costly Approaches (D. Weisdorf)
- Novel Approaches for Treating and Preventing GvHD (JF DiPersio)
- Design the Future of Hematopoietic Cell Transplantation (HCT) in Asia-Pacific Countries/Regions (S. Okamoto)

2018

November, APBMT (Taiwan)

ASBMT / EBMT / WBMT / APBMT Joint Symposium: Past, Now, and Future of Hematopoietic Stem Cell Transplantation

Co-Chairs: M. Yao, S. Okamoto

- Hematopoietic Stem Cell Transplantation: Where we have come from and where

- do we go? (J. Gajewski)
- Past, now and future of hematopoietic stem cell transplantation (EBMT prospective) (N. Kroger)
- How does the past predict the future of allogeneic transplantation: lessons for the field? (D. Weisdorf)
- How the APBMT is facing the challenge (S. Okamoto)

September, The 5th WBMT Workshop (Beijing, China)

International Experience and Data Sharing to Improve Access and Outcomes of Transplantation

1. Importance of creating the HSCT global outcome registration system
 - Global perspective of HSCT & registration (J. Szer)
 - WBMT Global Survey & registration (D. Niederwieser)
 - CIBMTR perspective of HSCT and registration (M Pasquini)
 - HSC Donor Registries: Challenges and Perspectives (C. Muller)
 - APBMT perspective: Importance of Outcome Data Sharing in Asian Pacific Region (Y. Kodera)
 - Current Activity Survey in the AP region (M. Iida)
 - Outcome Registry Current Status and future perspectives (Y. Atsuta)
 - Chinese perspective of HSCT and Activity Surveys; Difficulties in Data collection (XJ. Huang)
2. International Standards and Accreditation
 - Steps towards international accreditation: Lessons learned (S. Okamoto)
 - Addressing unproven cellular therapies (M. Koh)

April, WBMT/AfBMT (Morocco)

First Meeting of the African Blood and Marrow Transplantation Group: SCT in bone marrow failure

Co-Chairs: N. Novitzky, N. Khoubila

- Recent Progress in Diagnosis and Treatment of Inherited Bone Marrow Failure (S. Kojima)
- Acquired (S. Osman Ahmed)

2017

October, APBMT (Iran)

APBMT / WBMT Joint Session: Transplantation reports in the Asian pacific region & the progress of BMT in the world and Asian pacific region

Co-Chairs: A. Ghavamzadeh, S. Okamoto

- The progress of BMT in the Islamic Republic of Iran (A. Ghavamzadeh)

- The report of transplantation in all 15 BMT centers of Iran in the last five years (A. Hajifathali)
- The current status and future challenges of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) (S. Okamoto)
- The history, current status and future trends of WBMT (Y. Kodera)
- The report of transplantation in China five recent years (H. Huang)
- The advance of HSCT after the enforcement of “The Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations” in Japan (Y. Kodera)
- Outcome of autologous hematopoietic stem cell transplants for multiple myeloma in a single center in Sri Lanka (L. Gooneratne)
- The report of transplantation in Malaysia in five recent years (OT. Chuan)

Blood Cell Therapy

The official journal of APBMT



Blood Cell Therapy

The official journal of APBMT

Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly. Blood Cell Therapy was listed on PubMed Central (PMC) on January 20, 2023.

Online ISSN: 2432-7026

Journal homepage: <https://bct.apbmt.org/>

Aims and scope: Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy

Submission status of Blood Cell Therapy as of December 31, 2022

	2017	2018	2019	2020	2021	2022
Total Submitted	2	11	17	23	25	22
Total Decisoned						
Accept	1	9	12	17	21	16
Reject	1	2	3	6	3	3
Ongoing	0	0	0	0	1	3
Acceptance Rate	50%	82%	71%	74%	84%	73%
Article type						
State of the Art					7	6
Original Article	1	3	5	14	8	9
Review Article	0	3	2	1	2	
Case Report	1	4	4	6	6	3
Short Communication	0	1	2	1	2	4
Survey Report	0	0	4			
Guideline				1		

Authors by country/region

	2017	2018	2019	2020	2021	2022	Total
Australia		1	1		1		3
Bangladesh			1				1
Canada				1			1
China		1		1			2
India			2	6	4	8	20
Indonesia	1		1				2
Japan	1	7	6	8	6	11	42
Korea		1	1		1		3
Malaysia			1	2	1		4
Myanmar			1				1
Pakistan				1			1
Philippines				1	3	2	6
Singapore			1	2	2		5

Sri Lanka		1		1
Taiwan			1	1
Thailand			1	1
Vietnam			1	1
Germany			1	1
United Kingdom	1			1
United States		1		1
Jordan			1	1

Editorial Award of Blood Cell Therapy 2022

Minako Iida	The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region Volume 4 (2021) Issue 2 No.1 Pages 20-28 https://doi.org/10.31547/bct-2020-013
Dharma Choudhary	T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center Volume 4 (2021) Issue 2 No.2 Pages 29-34 https://doi.org/10.31547/bct-2020-014
Lawrence Cheng Kiat Ng	HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA – ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA Volume 4 (2021) Issue 4 No.4 Pages 92-100 https://doi.org/10.31547/bct-2021-007

Editorial Board Member List

Name	Commission	Country
Yoshiki Akatsuka	Editor-in-Chief	Japan
Tatsuo Ichinohe	Deputy Editor-in-Chief	Japan
Jeffrey Szer	Associate Editors	Australia
David Yeung		Australia
Haowen Xiao		China
Navin Khattry		India
Auro Viswabandya		India
Maryam Behfar		Iran
Ayami Yoshimi		Germany /Japan
Satoshi Takahashi		Japan
Junya Kanda		Japan
Shinichiro Okamoto		Japan
Jae Yong Kwak		Korea
Hee-Je Kim		Korea
Mickey Boon Chai Koh		Singapore
William YK Hwang		Singapore
Mei Zhang		China
Yuqian Sun		China
Alok Srivastava		India
Amir Hamidieh	Iran	
Mahmoud Aljurf	Saudi Arabia	
Daniel Weisdorf	USA	
Minako Iida	Editorial Office	Japan
Yukari Nakao	Editorial Office	Japan
Hiroe Namizaki	Editorial Office	Japan

*random order

Information for Submission

Manuscript submission rules for Authors : https://bct.apbmt.org/for_authors/

Editorial Policies : https://bct.apbmt.org/editorial_policies/

Guide for Reviewers : https://bct.apbmt.org/for_reviewers/

Submission : <https://mc.manuscriptcentral.com/bct>

List of the Accepted Articles Vol.5

Review Article

Optimizing Blood Stem Cell Transplants Through Cellular Engineering

Krystal Valerie Qian Ying Soh^{1,4}, William Ying Khee Hwang^{1,2,3}

¹National Cancer Centre Singapore, Singapore, SG 169610, ²Singapore General Hospital, Singapore, SG, ³Duke-NUS Medical School Singapore, Singapore, SG, ⁴Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SG

Blood Cell Therapy Volume 5 (2022) Issue 1 No.1 Pages 1-15

Submitted: June 21, 2021 Accepted: August 11, 2021 Published online: January 14, 2022

DOI: <https://doi.org/10.31547/bct-2021-008>

Original Article

Pattern of autologous stem cell transplants at a tertiary care government hospital, with emphasis on transplant outcomes with pre-harvest CD34+ level

Tuphan Kanti Dolai¹, Rajib De¹, Ankita Sen¹, Shuvra Neel Baul¹, Sumit Mitra¹, Subham Bhattacharya¹, Indrani Mondal¹, Kaushik Mukhopadhyay², Arnab Chattopadhyay¹, Shyamali Dutta¹, Prakas Kumar Mandal¹

¹Department of Haematology, Nil Ratan Sircar Medical College and Hospital, Kolkata, India, ²Department of Pharmacology, AIIMS, Kalyani, West Bengal, India

Blood Cell Therapy Volume 5 (2022) Issue 1 No.2 Pages 16-26

Submitted: July 30, 2021 Accepted: August 26, 2021 Published online: February 18, 2022

DOI: <https://doi.org/10.31547/bct-2021-010>

Case Report

Successful treatment of steroid-dependent gastrointestinal acute graft-versus-host disease with mesenchymal stromal cells administered more than 100 days after allo-HCT

Satoru Matsushima¹, Ryoji Kobayashi¹, Daiki Hori¹, Masato Yanagi¹, Koya Kodama¹, Hirozumi Sano¹, Daisuke Suzuki¹, Kunihiko Kobayashi¹

¹Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Japan

Blood Cell Therapy Volume 5 (2022) Issue 1 No.3 Pages 27-30

Submitted: August 13, 2021 Accepted: September 27, 2021 Published online: January 28, 2022

DOI: <https://doi.org/10.31547/bct-2021-013>

Case Report

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic

leukemia

Haruko Shima¹, Takahiro Ishikawa¹, Jumpei Ito¹, Katsura Emoto², Takumi Kurosawa¹, Dai Keino³, Fumito Yamazaki¹, Hiroaki Goto³, Hiroyuki Shimada¹

¹Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan, ²Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan, ³Division of Hematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan

Blood Cell Therapy Volume 5 (2022) Issue 1 No.4 Pages 31-34

Submitted: July 6, 2021 Accepted: October 7, 2021 Published online: January 28, 2021

DOI: <https://doi.org/10.31547/bct-2021-009>

Original Article

Quality of life and informational needs for allogeneic hematopoietic stem cell transplant among patients and their caregivers visiting long-term follow-up clinic

Shohei Nakajima^{1,2,3}, Kiyoko Kamibeppu^{1,2,4}

¹Department of Family Nursing, The University of Tokyo, Japan, ²Global Nursing Research Center, The University of Tokyo, Japan, ³Department of Nursing, The University of Tokyo Hospital, Japan, ⁴QOL Research Center for Children and Family, Japan

Blood Cell Therapy Volume 5 (2022) Issue 2 No.1 Pages 35-44

Submitted: June 2, 2021 Accepted: November 2, 2021 Published online: March 25, 2022

DOI: <https://doi.org/10.31547/bct-2021-005>

Original Article

Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single Centre Experience in Malaysia

Gilbert Wilfred^{1,2}, Tee Chuan Ong², Syed Abd Kadir SH Shahnaz², Ho Kim Wah², Edmund Syed Carlo³, Sathar Jameela², Sen Mui Tan²

¹Department of Haematology, Hospital Queen Elizabeth, Ministry of Health Malaysia Sabah, ²Department of Haematology, Hospital Ampang, Ministry of Health Malaysia Selangor, ³Centre of Clinical Research, Hospital Ampang, Ministry of Health Malaysia Selangor

Blood Cell Therapy Volume 5 (2022) Issue 2 No.2 Pages 45-53

Submitted: September 2, 2021 Accepted: November 28, 2021 Published online: April 8, 2022

DOI: <https://doi.org/10.31547/bct-2021-018>

Review Article

Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective

Shigeo Fujii^{1,2}, Jessica Cheng^{2,3}, Kimikazu Yakushijin^{2,4}, Chinadol Wanitpongpun^{2,5}

¹Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, ²Nutrition Support WG, Asia-Pacific

Blood and Marrow Transplantation group, ³Bone Marrow Transplant & Haematology, St Vincent's Public Hospital Sydney, Sydney, Australia, ⁴Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan, ⁵Hematology Unit, Department of Internal Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand

Blood Cell Therapy Volume 5 (2022) Issue 2 No.3 Pages 54-60

Submitted: November 8, 2021 Accepted: January 1, 2022 Published online: April 15, 2022

DOI: <https://doi.org/10.31547/bct-2021-024>

Original Article

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients

Ross Salvaris¹, Sam Salman², Sean O'Halloran³, David Joyce³, Navin Mathew¹, Julian Cooney¹, Matthew Wright¹, Paul Cannell¹, Duncan Purtill¹

¹Department of Haematology, Fiona Stanley Hospital, Western Australia, Australia, ²Medical School, University of Western Australia, Western Australia, Australia, ³Clinical Pharmacology and Toxicology, PathWest, Queen Elizabeth II Medical Centre, Western Australia, Australia

Blood Cell Therapy Volume 5 (2022) Issue 2 No.4 Pages 61-68

Submitted: September 13, 2021 Accepted: January 1, 2022 Published online: April 22, 2022

DOI: <https://doi.org/10.31547/bct-2021-019>

Original Article

Hematopoietic Stem Cell Transplantation is a cost-effective alternative to enzyme replacement therapy in Gaucher Disease

Fouzia N Aboobacker¹, Uday P Kulkarni¹, Anu Korula¹, Anup J Devasia¹, Sushil Selvarajan¹, Sharon Lionel¹, Eunice Sindhuvi¹, Alok Srivastava¹, Biju George¹, Aby Abraham¹

¹Department of Hematology, Christian Medical College, Vellore, Tamil Nadu.

Blood Cell Therapy Volume 5 (2022) Issue 3 No.1 Pages 69-74

Submitted: September 14, 2021 Accepted: January 9, 2022 Published online: May 20, 2022

DOI: <https://doi.org/10.31547/bct-2021-020>

Case Report

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome

Yukihiro Matsukawa¹, Kyohei Isshiki^{1,2}, Tomoo Osumi¹, Satoshi Fujiyama³, Hiroko Fukushima^{3,4}, Toru Uchiyama^{1,5}, Masaki Yamada⁶, Takao Deguchi¹, Ken-Ichi Imadome⁶, Kimikazu Matsumoto¹, Daisuke Tomizawa¹, Hidetoshi Takada^{3,4}, Masafumi Onodera⁵, Motohiro Kato¹

¹Children's Cancer Center, National Center for Child Health and Development, ²Department of Pediatrics, Saitama City Hospital, ³Department of Pediatrics, University of Tsukuba Hospital, ⁴Department of Child Health, Faculty of Medicine, University of Tsukuba, ⁵Department of Human Genetics, National Center for Child Health and Development,

Department of Advanced Medicine for Viral Infections, National Center for Child Health and Development
Blood Cell Therapy Volume 5 (2022) Issue 3 No.2 Pages 75-78
Submitted:September 25, 2021 Accepted:February 6, 2022 Published online:May 27, 2022
DOI:<https://doi.org/10.31547/bct-2021-021>

Case Report

Successful treatment of acute pancreatitis associated with late-onset acute liver GVHD after second allogeneic hematopoietic cell transplantation

Yuka Hosokawa¹, Tomomi Toubai¹, Rintaro Ohe², Masashi Hosokawa¹, Ryo Sato¹, Akane Yamada¹, Keiko Aizawa¹, Masahito Himuro¹, Satoshi Ito¹, Masakazu Yamamoto¹, Daniel Peltier³, Kenichi Ishizawa¹

¹Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan, ²Department of Pathology, Yamagata University Faculty of Medicine, Yamagata, Japan, ³Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

Blood Cell Therapy Volume 5 (2022) Issue 3 No.3 Pages 79-82
Submitted:November 1, 2021 Accepted:February 14, 2022 Published online:June 3, 2022
DOI:<https://doi.org/10.31547/bct-2021-023>

Short Communication

Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India

Niranjan S. Khaire¹, Prashant Chhabra¹, Dikshat G. Gupta¹, Aditya Jandial¹, Alka Khadwal¹, Kripa Shanker Kasudhan¹, Shaweta Kaundal¹, Madhu Chopra¹, Arihant Jain¹, Gaurav Prakash¹, Navneet S. Majhail², Pankaj Malhotra¹, Deepesh P. Lad¹

¹Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, Nashville, USA

Blood Cell Therapy Volume 5 (2022) Issue 3 No.4 Pages 83-86
Submitted:December 31, 2021 Accepted:February 28, 2022 Published online:June 10, 2022
DOI:<https://doi.org/10.31547/bct-2021-025>

Original Article

Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT

Minako Iida¹, Kaiyan Liu², Xiao Jun Huang², Wu Depei³, Yachiyo Kuwatsuka⁴, Joon Ho Moon⁵, Anthony Dodds⁶, Leonie Wilcox⁷, Bor-Sheng Ko⁸, Amir Ali Hamidieh⁹, Kim Wah Ho¹⁰, Artit Ungkanont¹¹, Aloysius Ho¹², Tasneem Farzana¹³, Joycelyn Sim¹⁴, Huynh Van Man¹⁵, Mafruha Akter¹⁶, Prasad Abeyasinghe¹⁷, Marjorie Rose Bravo¹⁸, Aye Aye Gyi¹⁹, Bishesh Sharma Poudyal²⁰, Khishigjargal Batshkh²¹, Alok Srivastava²², Shinichiro Okamoto²³, Yoshiko Atsuta^{24,25}

¹Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, ²Department of Hematology, Peking University Institute of Hematology, Beijing, China, ³Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China, ⁴Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan, ⁵Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, ⁶St. Vincent's Pathology, St. Vincent's Health Network, Sydney, and Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia, ⁷Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia, ⁸Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ⁹Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran, ¹⁰Department of Hematology, Hospital Ampang, Ampang Selangor, Malaysia, ¹¹Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand, ¹²Department of Haematology, Singapore General Hospital, Singapore, Singapore, ¹³Department of Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan, ¹⁴Department of Medicine, Queen Mary Hospital, Hong Kong, ¹⁵Stem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam, ¹⁶Bone marrow transplant unit, Department of Hematology, Dhaka Medical College and Hospital, Dhaka, Bangladesh, ¹⁷Department of Oncology, National Cancer Institute, Maharagama, Sri Lanka, ¹⁸St Luke's Medical Center Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, the Philippines, ¹⁹Department of Clinical Haematology, North Okkalapa General Hospital, Yangon, Myanmar, ²⁰Civil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, Nepal, ²¹Bone and Marrow transplantation team, Hematology Department, National First Central Hospital of Mongolia, Ulaanbaatar, Mongolia, ²²Department of Haematology, Christian Medical College Hospital, Vellore, India, ²³Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, ²⁴Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagakute, Japan, ²⁵Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan

Blood Cell Therapy Volume 5 (2022) Issue 4 No.1 Pages 87-98

Submitted: March 6, 2022 Accepted: March 28, 2022 Published online: July 8, 2022

DOI: <https://doi.org/10.31547/bct-2022-002>

Original Article

Human leukocyte antigen allele and haplotype frequencies in Singapore bone marrow donors and cord blood units

Alvin Ng Yu-Jin¹, Grace Benjamin Moshi^{2,3}, Arun Prasath⁴, Marieta Chan³, Poon Limei Michelle¹, Loh Chee Khiong Charles⁵, Louise Chos, Valerie Voon³, Seng Zi Jings⁵, Phang Chew Yen³, Aloysius Yew Leng Ho⁴

¹ National University Hospital, Singapore, ² KK Women's and Children's Hospital, Singapore, ³ Health Sciences Authority, Singapore, ⁴ Singapore Cord Blood Bank, Singapore, ⁵ Bone Marrow Donor Programme, Singapore

Blood Cell Therapy Volume 5 (2022) Issue 4 No.2 Pages 99-106

Submitted: May 30, 2022 Accepted: August 15, 2022 Published online: November 11, 2022

DOI: <https://doi.org/10.31547/bct-2022-004>

Original Article

Effect of Early Nutritional Support on Quality of Life by EORTC QLQ-C30 in Allogeneic Hematopoietic Stem Cell Transplantation

Ayaka Inden^{1,2}, Takayoshi Tsukahara¹, Eiko Tachibana¹, Yasuyuki Nagata³, Takaaki Ono⁴, Akihiko Kato²

¹ Graduate School of Nutritional Sciences, Nagoya University of Arts and Sciences, Aichi, Japan, ² Clinical Nutrition Unit, Hamamatsu University Hospital, Shizuoka, Japan, ³ Division of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan, ⁴ Department of Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Shizuoka, Japan

Blood Cell Therapy Volume 5 (2022) Issue 4 No.3 Pages 107-115

Submitted: July 16, 2022 Accepted: October 3, 2022 Published online: November 25, 2022

DOI: <https://doi.org/10.31547/bct-2022-007>

State of the Art

Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy

Yoshikane Kikushige^{1,2}

¹ Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Japan, ² Center for Cellular and Molecular Medicine, Kyushu University Hospital, Japan

Blood Cell Therapy Volume 5 (2022) Special Edition No.1 Pages S1-S5

Submitted: September 9, 2022 Accepted: September 12, 2022 Published online: December 23, 2022

DOI: <https://doi.org/10.31547/bct-2022-010>

State of the Art

Alternate Donor Transplantation

William YK Hwang^{1,2,3}, Piyanuch Kongtim⁴, Navneet S Majhail⁵, Ming Yao⁶

¹ National Cancer Centre Singapore, ² Singapore General Hospital, ³ Duke-NUS Medical School Singapore, ⁴ Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology-Oncology, Department of Medicine, University of California Irvine, CA, USA, ⁵ Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA, ⁶ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Blood Cell Therapy Volume 5 (2022) Special Edition No.2 Pages S6-S14

Submitted: September 21, 2022 Accepted: September 27, 2022 Published online: December 23,

2022 DOI: <https://doi.org/10.31547/bct-2022-012>

State of the Art

The activities and regulatory landscape of cellular therapies including

hematopoietic cell transplantation in the world

Shinichiro Okamoto^{1,2}, Miguel-Angel Perales^{3,4}, Anna Suredas⁵, Dietger Niederwieser^{6,7,8}

¹ Keio University, Tokyo, Japan, ² Asia-Pacific Blood and Marrow Transplantation Group (APBMT), ³ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA, ⁴ Department of Medicine, Weill Cornell Medical College, New York, USA, ⁵ Clinical Hematology Department. Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, ⁶ University of Leipzig, Germany, ⁷ Aichi Medical University School of Medicine, Nagakute, Japan, ⁸ Lithuanian University of Health Sciences, Kaunas, Lithuania

Blood Cell Therapy Volume 5 (2022) Special Edition No.3 Pages S15-S24

Submitted: September 26, 2022 Accepted: October 11, 2022 Published online: December 23, 2022

DOI: <https://doi.org/10.31547/bct-2022-013>

State of the Art

Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

Yasuhito Nannya¹, Auro Viswabandya², Peihua Lu³

¹ Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, ² Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, ³ Lu Daopei Hospital, Beijing Lu Daopei Institute of Hematology

Blood Cell Therapy Volume 5 (2022) Special Edition No.4 Pages S25-S33

Submitted: October 4, 2022 Accepted: November 1, 2022 Published online: December 23, 2022

DOI: <https://doi.org/10.31547/bct-2022-015>

Appendix

Cooperate Members

Annual sponsorship	Center for Supporting Hematology-Oncology Trials (C-SHOT) in Japan
	AIR WATER
International sponsorship for the APBMT 2022 India	Jazz
	Gilead Sciences
	Miltenyi Biotec
	Fresenius Kabi

APBMT Annual Report 2022

APBMT officers

President



Shinichiro Okamoto
Department of Medicine
Keio University School of Medicine
35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
Tel: +81 3 3335 1221
okamoto.a7@keio.jp

Secretariat office

E-mail: office@apbmt.org

Website: <http://www.apbmt.org>

Department of Promotion for Blood and Marrow
Transplantation

Aichi Medical University School of Medicine

1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan

Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180



Minako Iida
miida@aichi-med-u.ac.jp



Yukari Nakao
yukari-nakao@aichi-med-u.ac.jp



Hiroe Namizaki
namizaki@aichi-med-u.ac.jp

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT